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OUTLOOK

Anticipating resistance to KRAS
inhibition: a novel role for USP21
in macropinocytosis regulation
Howard C. Crawford
Henry Ford Pancreatic Cancer Center, Henry Ford Health System, Detroit, Michigan 48202, USA

Pancreatic ductal adenocarcinoma (PDAC) is one of the
deadliest cancers. Virtually all PDAC harbors an oncogenic mutation in the KRAS gene, making it the prime target
for therapy. Most previous attempts to inhibit KRAS
directly have been disappointing, but recent success in
targeting some KRAS mutants presages a new era in
PDAC therapy. Models of PDAC have predicted that identifying KRAS inhibitor resistance mechanisms will be
critical. In this issue of Genes & Development, Hou and
colleagues (pp. 1327–1332) identify one such mechanism
in which the deubiquitinase USP21 up-regulates the nutrient-scavenging process of macropinocytosis, rescuing
PDAC cells from Kras extinction.

Pancreatic ductal adenocarcinoma (PDAC) is the most
common form of pancreatic cancer and the third most
deadly cancer in the United States (Siegel et al. 2021).
Very little progress has been made in treating PDAC
over the past several decades, due in part to most cases
presenting as metastatic disease upon diagnosis and its
resistance to conventional and targeted therapies. Its
relatively homogenous mutational landscape, including
oncogenic mutation of KRAS, found in virtually all cases
of PDAC, together with inactivation of tumor suppressor
genes such as TRP53, CDKN2A, and SMAD4, has facilitated the development of some of the most useful preclinical mouse models of any tumor type (Hingorani et al.
2005; Ying et al. 2012). Among other things, these mouse
models have confirmed that mutant Kras (Kras∗ ) is sufficient to initiate transformation in the pancreas and that
extinguishing Kras∗ expression after progression to adenocarcinoma leads to widespread tumor regression (Ying
et al. 2012), indicating that, even in these later stages, pancreatic tumor cells remain addicted to constitutive Kras∗
signaling, reinforcing its status as the prime therapeutic
target in the treatment of PDAC.
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Unfortunately, KRAS∗ has long been considered
“undruggable” for a variety of reasons. That status
changed very recently with the development of small
molecules that specifically target the G12C KRAS∗ protein, which has shown clinical efficacy (Herdeis et al.
2021). However, this specific KRAS mutation is found in
only a small fraction (∼1%) of human PDACs compared
with G12D (41%), G12V (34%), or G12R (16%) (Waters
and Der 2018). Fortunately, small molecules that target
some of these more common KRAS mutants are in development (Herdeis et al. 2021), giving hope for the future of
effective treatment of the vast majority of PDAC patients.
With viable KRAS inhibitors finally making headway,
anticipating mechanisms of resistance to Kras inhibition
is paramount. Indeed, while extinguishing Kras∗ expression in PDAC mouse models causes tumor regression, resistant tumors do arise over time. In previous studies,
DePinho and colleagues (Kapoor et al. 2019) have found
that up-regulation of the Hippo pathway transcription factor, YAP1, is one mechanism that compensates for loss of
Kras∗ activity in ∼30% of resistant tumors examined. In a
subsequent study, the same group used a gain-of-function
screen using a library encoding 284 epigenetic regulators,
leading to the identification of HDAC5 expression as sufficient to compensate for the loss of Kras∗ by modifying
the inflammatory tumor microenvironment (Hou et al.
2020).
This prior epigenetic regulator screen revealed several
additional suspects that had the potential to help PDAC
overcome its Kras∗ addiction. The second most prominent hit was Usp21, a deubiquitinase that is amplified
and overexpressed in ∼20% of PDAC patient samples
(Hou et al. 2019). USP21 is best known for its nuclear
function as a histone deubiquitinase, although nuclear
USP21 promotes pancreatic tumor growth by deubiquitinating the transcription factor TCF7, amplifying canonical Wnt signaling, and enhancing tumor stem cell
properties (Hou et al. 2019). In the current study, Hou
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et al. (2021) present an elegant, textbook example of scientific sleuthing to uncover a novel mechanism behind
USP21’s ability to overcome the loss of Kras∗ activity.
Using mutant forms of USP21 that enforce localization
to the nucleus or the cytoplasm, the investigators make
the surprising discovery that the relevant Kras∗ -bypassing
activity occurs in the cytoplasm, rather than in the nucleus. USP21 did not break cells free of Kras∗ dependency
through a straightforward reactivation of pathways downstream from Kras∗ , as MEK/ERK signaling remained low,
nor was it associated with up-regulation of Yap activity, a
previously identified mechanism of Kras∗ escape. Using
transcriptomic analysis, the investigators discovered
that USP21 overexpression up-regulates mTOR-associated signaling, with metabolomic analysis revealing an association with increased amino acid levels, a known
activator of mTOR. Sifting through the usual suspects
that could be responsible for this increase in amino acids,
the investigators found no associated up-regulation of de
novo amino acid biosynthesis, no reduction in protein
translation, and no alterations in amino acid transporter
expression. They also did not find an association with
the breakdown of intracellular proteins, as USP21 activity
decreased autophagosome formation and autophagy. Having systematically eliminated each of these candidate activities, one remained: macropinocytosis, a mechanism of
nutrient scavenging that is critical for Kras mutant PDAC
cell survival. Indeed, USP21 expression restored macropinocytosis in Kras∗ -extinguished cells, and macropinocytosis inhibitors thwarted USP21-induced Kras∗ escape.
Finally, to identify the direct target of USP21 activity,
the investigators used the protein as bait to capture a single interacting culprit: MARK3, a microtubule-binding kinase and regulator of microtubule dynamics (Sandí et al.
2017). Closing the case, the investigators confirmed that
MARK3 is deubiquitinated by USP21 and is necessary
and sufficient for Kras∗ -independent growth, tumor formation, and macropinocytosis, with the latter being necessary for Mark3-induced tumor growth.
With their collective studies (Hou et al. 2019), together
with USP21 ablation in mice having no obvious deleterious effects (Pannu et al. 2015), the investigators have
made a compelling case for USP21 as a viable therapeutic
target in PDAC, either on its own or in combination with
KRAS∗ inhibition. However, as with any compelling story, some mysteries remain. For instance, the original impetus for exploring the role of USP21 was its
amplification in a significant number of pancreatic cancers (Hou et al. 2019). Would its overcoming the metabolic stress caused by KRAS∗ inhibition be limited to these
USP21-amplified tumors, or is USP21 amplification itself
indicative of an adaptive mechanism that deploys when
cells are faced with such stress? It would also be fascinating to explore how the cytoplasmic and nuclear functions
of USP21 may complement one another, or even synergize. Finally, the finding that MARK3 is required for macropinocytosis in this system is itself a novel discovery. If it
is required for macropinocytosis in general, it also may
qualify as a novel therapeutic target for treating PDAC.
These and other questions will likely be answered in fu-
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ture studies. In the interim, while the case of effective
KRAS∗ inhibitors is being cracked, the more mechanisms
of resistance to the loss of KRAS∗ activity that are identified, the better prepared we will be to defeat this devastating and deadly disease once and for all.
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